XENE

Wolf Popper LLP is investigating potential securities claims on behalf of Xenon Pharmaceuticals investors following a significant stock price decline. On September 17, 2026, Xenon announced a voluntary pause in new patient enrollment in its MDD and bipolar depression clinical studies due to neuropsychiatric adverse events. The announcement triggered a 30.7% stock price drop, falling from approximately $57.35 to $39.75 per share on heavy trading volume.

Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback.